What is the therapeutic effect of pomalidomide and is there any clinical feedback?

Pomalidomide(Pomalidomide), as a new generation of immunomodulator, plays an increasingly important role in the treatment of multiple myeloma. It is a structural analog of lenalidomide, but has been optimized at the molecular level, so it has stronger anti-myeloma activity and a lower risk of side effects. The therapeutic mechanism of pomalidomide is mainly by regulating the immune system, enhancing the activity of T cells and natural killer cells, while inhibiting the microenvironment of myeloma cells and slowing down tumor growth. It is often used in combination with dexamethasone and provides a new treatment option in patients who have failed treatment with lenalidomide or proteasome inhibitors.

Based on real-world feedback from multiple centers around the world, pomalidomide demonstrated stable disease control in patients with multiple myeloma who had previously failed multiple lines of regimens. Although it is not a cure, it can effectively prolong disease progression-free survival and overall survival time. Especially in patients with high-risk gene mutations or complex chromosomal abnormalities, it can still maintain a certain effect. During patient use, common adverse reactions include anemia, fatigue and leukopenia, but they can be better managed through dose adjustment or symptomatic treatment.

In clinical feedback, doctors generally believe that pomalidomide is convenient to take and helps improve patients' treatment compliance. Its oral dosage form is suitable for long-term use and also provides the possibility of home treatment for patients who cannot frequently be hospitalized. Especially during the epidemic, pomalidomide has been more adopted because it reduces reliance on intravenous treatment. Nonetheless, the treatment plan must be formulated by a professional hematologist based on the patient's condition, and medication must not be adjusted on your own.

Taken together, pomalidomide has gradually become a standard second-line or third-line treatment drug for relapsed or refractory myeloma. Its clinical status is constantly improving and it has been widely recognized by the global medical community.

Reference materials:https://en.wikipedia.org/wiki/Pomalidomide